probability of survival for x additional years, given y years of accumulated survival. EFS time points used in the CS models consisted of from 1 year up to 10 years after surgery. Second, separate multivariable Cox regression (MCR) models predicting CSM
Search Results
Carlotta Palumbo, Francesco A. Mistretta, Sophie Knipper, Angela Pecoraro, Zhe Tian, Shahrokh F. Shariat, Fred Saad, Claudio Simeone, Alberto Briganti, Alessandro Antonelli, and Pierre I. Karakiewicz
Kimberly L. Johung and Stacey M. Stein
of epirubicin/cisplatin/fluorouracil (ECF) compared with surgery alone, 1 and the Intergroup 0116 trial showed a survival benefit with postoperative chemoradiation (CRT) to 45 Gy and concurrent fluorouracil and leucovorin. 2 More recently, the
Brian Badgwell
multidisciplinary clinical evaluation. This approach is not emphasized in regions of the world where a surgery-first approach is standard of care, radiation therapy is infrequently used, and many cancers are found at an early stage and don't require adjuvant
Renata R. Urban, Hao He, Rafael Alfonso-Cristancho, Melissa M. Hardesty, and Barbara A. Goff
that they treat. In preparation for payment reform, ASCO developed a bundled payment model for the treatment of patients with cancer using chemotherapy. 2 , 3 Ovarian cancer is a complex disease requiring surgery and chemotherapy to achieve the best
David Scott Miller, Gini Fleming, and Marcus E. Randall
; 8 : 423 – 442 . 9 Morrow CP Bundy BN Homesley HD . Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group study
Jaffer A. Ajani, James S. Barthel, Tanios Bekaii-Saab, David J. Bentrem, Thomas A. D'Amico, Prajnan Das, Crystal Denlinger, Charles S. Fuchs, Hans Gerdes, James A. Hayman, Lisa Hazard, Wayne L. Hofstetter, David H. Ilson, Rajesh N. Keswani, Lawrence R. Kleinberg, Michael Korn, Kenneth Meredith, Mary F. Mulcahy, Mark B. Orringer, Raymond U. Osarogiagbon, James A. Posey, Aaron R. Sasson, Walter J. Scott, Stephen Shibata, Vivian E. M. Strong, Mary Kay Washington, Christopher Willett, Douglas E. Wood, Cameron D. Wright, and Gary Yang
laparoscopic staging differ among various NCCN institutions. In some, laparoscopic staging is reserved for medically fit patients with potentially resectable disease, specifically when chemoradiotherapy or surgery is considered. In medically unfit patients
Saurabh Parasramka, Quan Chen, Bin Huang, Peng Wang, and Zin Myint
Background: Non-metastatic muscle invasive bladder cancer (MIBC) is treated with radical cystectomy and survival is closely associated with final pathologic staging. For patients undergoing primary surgery there is evidence that delay > 90 days
Joseph S. Friedberg
Performing surgery for malignant pleural mesothelioma “is like scraping paint off a wall: there is always going to be microscopic disease left,” declared Joseph S. Friedberg, MD, Chief of Thoracic Surgery at Penn Presbyterian Medical Center
Vivek Verma
Stereotactic ablative radiotherapy (SABR) is highly controversial compared with surgery for early-stage operable lung cancer. Initial observational data in operable patient cohorts showed that outcomes for SABR were roughly equal to those of
Adrian Legaspi, Vanitha Vasudevan, Amit Sastry, Jeronimo Garcialopez de Llano, and Marice Ruiz-Conejo
Background: Minimally invasive surgical techniques improve metrics designed to measure quality and efficiency. Compared to open surgery (OS) and laparoscopy (LAP), robotic assisted colorectal surgery (RACS) has shorter length of stay (LOS), less
